Related Experiment Video
Updated: Apr 5, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment
I Lipska1, J Hoekman2, N McAuslane1
1Center for Innovation in Regulatory Science, Warsaw, Poland.
Abstract:
An early access pathway of conditional approval for potentially beneficial medicines is available within the European regulatory framework. However, marketing authorization does not necessarily result in recommendations for public funding by health technology assessment (HTA) agencies. As conditional approval goes along with less than complete data on benefits and risks of a treatment option for a high medical need, this raises the question how HTA decision-making is affected by these uncertainties.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
FDA Approved Drugs: Changes to Approved Drugs
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Regulation

